IBD: Ulcerative Colitis

What’s Health Canada Saying about Biosimilars?

A biosimilar biologic drug, or biosimilar, is a drug demonstrated to be highly similar to a biologic drug that was already authorized for sale (known as the reference biologic drug). Biosimilars are approved based on a thorough comparison to a reference drug and may enter the market after the expiry of reference drug patents and data protection. Watch this video to get more insight into what Health Canada is saying about biosimilars!

This video was made possible by an unrestricted educational grant by Pfizer Canada.

Can immunocompromised patients with IBD get the COVID vaccine?

COVID-19 Vaccinations in Immunocompromised Patients with Inflammatory Bowel Disease (IBD)

Are COVID-19 vaccinations in immunocompromised patients with IBD safe? CDHF’s association – the Canadian Association of Gastroenterology (CAG) recently provided guidance for mRNA COVID-19 vaccinations in […]

Tests and Treatment

Treating Crohn’s Disease Although several drugs are useful in controlling these conditions, as yet a cure has not been found. Since the disease is not curable, […]

Signs & Symptoms

The most common symptoms of ulcerative colitis are abdominal pain, diarrhea, blood in the stool and false urges to have a bowel movement. Abdominal pain (cramping): Ulcerative […]

What’s Health Canada Saying about Biosimilars?

https://www.youtube.com/watch?v=6DkzQFdyNuY

IBD: Ulcerative Colitis

What’s Health Canada Saying about Biosimilars?

Related Articles

What’s Health Canada Saying about Biosimilars?